Aim: Coagulation disorders may develop in association with severe acute pancreatitis (AP). Plasma thrombin-antithrombin III complex (TAT) levels are one of the principal markers of coagulation disorder. The purpose of this study was to evaluate TAT and other hemostatic parameters in patients with AP and to examine whether or not these parameters indicate the severity of AP. Method: Forty-six patients with AP (14 severe, 32 non-severe) and a 30-member healthy control group were recruited. The severity of AP was determined using the revised Atlanta classification. ELISA was used to measure patients’ plasma TAT levels. Results: The TAT levels of AP patients at presentation were higher than those of the control group (p = 0.005). The plasma TAT levels of patients with severe AP were also significantly higher than those of patients with non-severe AP (p = 0.05) and of the control group (p < 0.001). The general accuracy, sensitivity and specificity of TAT levels in predicting the severity of AP were 77.4, 77.8, and 77.3% respectively. Conclusion: The coagulation cascade was activated in the AP patients in our study, and this was shown to become more pronounced as severity of the disease increased. Plasma TAT levels at the time of presentation in patients with AP can be used as a marker for predicting the severity of the disease.

Keywords:
Thrombin-antithrombin complex, Acute pancreatitis, Severity of pancreatitis, Coagulation
1.
Zhu Y, Pan X, Zeng H, He W, Xia L, Liu P, Zhu Y, Chen Y, Lv N: A study on the etiology, severity, and mortality of 3260 patients with acute pancreatitis according to the revised atlanta classification in Jiangxi, China over an 8-year period. Pancreas 2017; 46: 504–509.
2.
Fagenholz PJ, Castillo CF, Harris NS, Pelletier AJ, Camargo CA Jr: Increasing United States hospital admissions for acute pancreatitis, 1988–2003. Ann Epidemiol 2007; 17: 491–497.
3.
Koutroumpakis E, Slivka A, Furlan A, Dasyam AK, Dudekula A, Julia B. Greer JB, Whitcomb DC, Yadav D, Papachristou G: Management and outcomes of acute pancreatitis patients over the last decade: a US tertiary-center experience. Pancreatology 2017; 17: 32–40.
4.
Fisher JM, Gardner TB: The “golden hours” of management in acute pancreatitis. Am J Gastroenterol 2012; 107: 1146–1150.
5.
Jacob AO, Stewart P, Jacob O: Early surgical intervention in severe acute pancreatitis: Central Australian experience. ANZ J Surg 2016; 86: 805–810.
6.
Ranson JH, Lackner H, Berman IR, Schinella R: The relationship of coagulation factors to clinical complications of acute pancreatitis. Surgery 1977; 81: 502–511.
7.
Maeda K, Hirota M, Ichihara A, Ohmuraya M, Hashimoto D, Sugita H, Takamori H, Kanemitsu K, Baba H: Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas 2006; 32: 87–92.
8.
Kakafika A, Papadopoulos V, Mimidis K, Mikhailidis DP: Coagulation, platelets, and acute pancreatitis. Pancreas 2007; 34: 15–20.
9.
Hamada S, Masamune A, Kikuta K, Shimosegawa T: Disseminated intravascular coagulation on admission predicts complications and poor prognosis of acute pancreatitis: analysis of the nationwide epidemiological survey in Japan. Pancreas 2017; 46:e15–e16.
10.
Dumnicka P, Maduzia D, Ceranowicz P, Olszanecki R, Drozdz R, Kusnierz-Cabala B: The Interplay between Inflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: clinical implications. Int J Mol Sci 2017; 18:pii:E354.
11.
Makhija R, Kingsnorth AN: Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002; 9: 401–410.
12.
Bhatia M. Inflammatory response on the pancreatic acinar cell injury. Scand J Surg 2005; 94: 97–102.
13.
Seitz R, Egbring R, Wagner C, Dati F: [Thrombinantithrombin III complex (TAT): a marker for activation of intravascular coagulation]. Internist (Berl) 1990; 31: 69–74.
14.
Deguchi K, Noguchi M, Yuwasaki E, Endou T, Deguchi A, Wada H, Murashima S, Nishikawa M, Shirakawa S, Tanaka K, et al: Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol 1991; 38: 86–89.
15.
Montaner J: Blood biomarkers to guide stroke thrombolysis. Front Biosci (Elite Ed) 2009; 1: 200–208.
16.
Koyama K, Madoiwa S, Nunomiya S, Koinuma T, Wada M, Sakata A, Ohmori T, Mimuro J, Sakata Y: Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Critical Care 2014; 18:R13.
17.
Kalambokis GN, Oikonomou A, Baltayiannis G, Christou L, Kolaitis NI, Tsianos EV: Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis. Hepatol Res 2016; 46:E36–E44.
18.
Salomone T, Tosi P, Palareti G, Tomassetti P, Migliori M, Guariento A, et al: Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas 2003; 26: 111–116.
19.
Radenkovic D, Bajec D, Ivancevic N, Milic N, Bumbasirevic V, Jeremic V, Djukic V, Stefanovic B, Stefanovic B, Milosevic-Zbutega G, Gregoric P: D-dimer in acute pancreatitis: a new approach for an early assessment of organ failure. Pancreas 2009; 38: 655–660.
20.
Sayilir A, Beyazit Y, Yesil Y, Albayrak M, Ekiz F, Celik T, Suvak B, Torun S, Ibis M: Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis. Clin Res Hepatol Gastroenterol 2012; 36: 498–504.
21.
Banks PA, Bollen TL, Dervenis C, et al; Acute Pancreatitis Classification Working Group: Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102–111.
22.
Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23: 1638–1652.
23.
Badhal SS, Sharma S, Saraya A, Mukhopadhyay K: Prognostic significance of D-dimer, natural anticoagulants and routine coagulation parameters in acute pancreatitis. Trop Gastroenterol 2012; 33: 193–199.
24.
Lisman T, Porte RJ: Activation and regulation of hemostasis in acute liver failure and acute pancreatitis. Semin Thromb Hemost 2010; 36: 437–443.
25.
Cuthbertson CM, Christophi C: Disturbances of the microcirculation in acute pancreatitis. Br J Surg 2006; 93: 518–530.
26.
Tomkötter L, Erbes J, Trepte C, Hinsch A, Dupree A, Bockhorn M, Mann O, Izbicki JR, Bachmann K: The effects of pancreatic microcirculatory disturbances on histopathologic tissue damage and the outcome in severe acute pancreatitis. Pancreas 2016; 45: 248–253.
27.
Gullo L, Cavicchi L, Tomassetti P, Spagnolo C, Freyrie A, D'Addato M: Effects of ischemia on the human pancreas. Gastroenterology 1996; 111: 1033–1038.
28.
Vollmar B, Menger MD: Microcirculatory dysfunction in acute pancreatitis. A new concept of pathogenesis involving vasomotion-associated arteriolar constriction and dilation. Pancreatology 2003; 3: 181–190.
29.
Di M, Liu H, Yang Z, Bonis PA, Tang J, Lau J: Prediction models of mortality in acute pancreatitis in adults: a systematic review. Ann Intern Med 2016; 165: 482–490.
30.
Staubli SM, Oertli D, Nebiker CA: Laboratory markers predicting severity of acute pancreatitis. Crit Rev Clin Lab Sci 2015; 52: 273–283.
31.
Meher S, Mishra TS, Sasmal PK, Rath S, Sharma R, Rout B, Sahu MK: Role of biomarkers in diagnosis and prognostic evaluation of acute pancreatitis. J Biomark 2015; 2015: 519534.
32.
Yang N, Hao J, Zhang D: Antithrombin III and D-dimer levels as indicators of disease severity in patients with hyperlipidaemic or biliary acute pancreatitis. J Int Med Res 2017; 45: 147–158.
33.
Bouma BN, Mosnier LO: Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagülation and fibrinolysis. Pathophysiol Haemost Thromb 2004; 33: 375–381.
34.
Bajzar L, Jain N, Wang P, Walker JB: Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 2004; 32: 320–324.
35.
Beyazit B, Sayilir A, Tanoglu A, Kekilli M, Kocak E, Ekiz F, Tas A: Plasma thrombin-activatable fibrinolysis inhibitor levels correlate with the disease activity of ulcerative colitis. Intern Med 2016; 55: 1831–1836.
36.
Peters MJ, Nurmohamed MT, van Eijk IC, Verkleij CJ, Marx PF: Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1232–1233.
37.
Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F: Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer. Tumor Biol 2012; 33: 1519–1525.
38.
Vollmar B, Menger MD: Microcirculatory dysfunction in acute pancreatitis. A new concept of pathogenesis involving vasomotion-associated arteriolar constriction and dilation. Pancreatology 2003; 3: 181–190.
39.
Lu XS, Qiu F, Li YX, Li JQ, Fan QQ, Zhou RG: Effect of lower-molecular weight heparin in the prevention of pancreatic encephalopathy in the patient with severe acute pancreatitis. Pancreas 2010; 39: 516–519.
40.
Warzecha Z, Dembinski A, Ceranowicz P, Dembinski M, Sendur R, Cieszkowski J, Sendur P, Tomaszewska R: Heparin inhibits protective effect of ischemic preconditioning in ischemia/reperfusion-induced acute pancreatitis. J Physiol Pharmacol 2012; 63: 355–365.
41.
Hagiwara S, Iwasaka H, Shingu C, Matsumoto S, Uchida T, Noguchi T: Antithrombin III prevents cerulein-induced acute pancreatitis in rats. Pancreas 2009; 38: 746–751.
42.
Hackert T, Sperber R, Hartwig W, et al: P-selectin inhibition reduces severity of acute experimental pancreatitis. Pancreatology 2009; 9: 369–374.
43.
Ke L, Ni HB, Tong ZH, Li WQ, Li N, Li JS: Efficacy of continuous regional arterial infusion with low-molecular-weight heparin for severe acute pancreatitis in a porcine model. Shock 2014; 41: 443–448.
44.
Sheng LX, Fu Q, Qin LJ, Qiao FQ, Guang ZR, Hang AY, Cheng ZK, Xiong LY: Low molecular weight heparin in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study. Asian J Surg 2009; 32: 89–94.
45.
Pettila V, Kyhala L, Kylanpaa ML, Leppaniemi A, Tallgren M, Markkola A, Puolakkainen P, Repo H, Kemppainen E: APCAP-activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care 2010; 14:R139.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.